Back to results

University of the Western Cape

Therapeutic and virological outcomes in adults living with HIV / AID at 6 and 12 months after initiation of first-line highly active antiretroviral therapy in an urban population in Namibia

Abstract

dc:description.abstract

Antiretroviral regimens have side effects that can threaten adherence by patients resulting in evolution of viral resistance due to suboptimal drug levels. Studies have shown that drug adherence of at least 80% can result in viral load suppression. There is no literature on the association between the level of adherence to antiretroviral therapy and the degree of virological suppression in Namibia. The aim of the present study was to determine the therapeutic and virological outcomes in HIV/AIDS patients at 6 and 12 months after initiation of highly-active antiretroviral therapy (HAART) in an urban population in Namibia. The distribution of viral load results showed a low uptake (35%) of virological monitoring at 6 month time point and even lower (12%) at 12 months. A conservative viral load threshold for virological response is required in the Namibian setting. The current adherence level of >80% encourage increased ARV therapy rollout. Poor virological outcome was associated with self-reported adherence.

Degree

thesis:*
Grantor dc:publisher.institution
University of the Western Cape
Year dc:date.issued
2010

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Gorova, Vivianne Inganai
Advisors dc:contributor.advisor
  • Igumbor, Ehimario
  • Kasvosve, Ishmael

Subjects

dc:subject × 10

Chain of custody

source
Harvested from
University of the Western Cape
Base URL
uwcscholar.uwc.ac.za:8443/server/oai/request
Last updated
2026-07-24
Source record
OAI-PMH GetRecord
citation

Gorova, Vivianne Inganai. Therapeutic and virological outcomes in adults living with HIV / AID at 6 and 12 months after initiation of first-line highly active antiretroviral therapy in an urban population in Namibia. University of the Western Cape, 2010.